Screening methods for Anti inflammatory drugs.pptx

screeening

1. Screening methods for Anti inflammatory drugs

2. Introduction to Anti-Inflammatory Drugs Mechanisms of Action Definition : Anti-inflammatory drugs reduce inflammation, the body's response to injury or infection. Classes : Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Corticosteroids

3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Mechanism : Inhibit cyclooxygenase (COX) enzymes (COX-1 and COX-2) Block conversion of arachidonic acid to prostaglandins Reduce production of prostaglandins Decrease inflammation, pain, and fever Examples : Ibuprofen Aspirin Naproxen

4. Corticosteroids Mechanism : Mimic adrenal cortex hormones Inhibit phospholipase A2 activity Decrease release of arachidonic acid from cell membrane phospholipids Reduce production of inflammatory mediators (prostaglandins, leukotrienes ) Suppress immune response by reducing activity and proliferation of immune cells Examples : Prednisone

5. Process of Inflammation Inflammation Overview Definition : A complex biological response to harmful stimuli such as pathogens, damaged cells, or irritants. Purpose : Remove injurious stimuli and initiate healing. Types : Acute Inflammation Chronic Inflammation

6. Acute Inflammation Initiation : Triggered by infections, tissue injuries, and immune reactions. Vascular Changes : Blood vessels dilate (vasodilation). Increased blood flow leads to redness (erythema) and heat. Increased Permeability : Blood vessels become more permeable. Plasma proteins and leukocytes enter the tissue, causing swelling (edema). Cellular Events : Neutrophils migrate to the site through chemotaxis . Neutrophils perform phagocytosis to destroy pathogens and debris. Inflammatory mediators such as histamine, prostaglandins, and cytokines (e.g., TNF- α, IL-1, IL-6) amplify the response. Resolution : Anti-inflammatory signals terminate the response once stimuli are removed. Macrophages clear dead cells and debris. Promotes tissue repair.

7. Chronic Inflammation Persistence of Stimuli : Occurs when the response fails to eliminate harmful stimuli or when they persist for a prolonged period. Characterized by continuous presence of inflammatory cells, tissue destruction, and healing attempts. Cellular Infiltration : Involves mononuclear cells (macrophages, lymphocytes, plasma cells). These cells release cytokines and growth factors that perpetuate the inflammatory response. Tissue Destruction and Repair : Leads to simultaneous tissue destruction and repair. Fibroblasts and endothelial cells contribute to fibrosis (scarring) and angiogenesis (new blood vessel formation). Granuloma Formation : In some conditions, granulomas form from aggregated macrophages surrounded by a layer of lymphocytes. Indicative of chronic infections, autoimmune diseases, and certain foreign bodies.

8. Models and Methods for Screening Anti-Inflammatory Drugs 1. Carrageenan-Induced Paw Edema in Rats Purpose : Model for acute inflammation. Method : Carrageenan injection into the rat's paw. Assessment : Reduction in paw swelling. Utility : Screening NSAIDs. . Cotton Pellet Granuloma in Rats Purpose : Model for chronic inflammation. Method : Subcutaneous implantation of cotton pellets. Assessment : Reduction in granuloma weight. Utility : Studying corticosteroids.

9. TPA-Induced Ear Edema in Mice Purpose : Model for acute inflammation. Method : TPA application on the mouse ear. Assessment : Reduction in ear swelling and erythema. Utility : Screening topical anti-inflammatory agents. Collagen-Induced Arthritis (CIA) in Mice and Rats Purpose : Model for rheumatoid arthritis. Method : Immunization with collagen. Assessment : Clinical signs and biomarkers of arthritis. Utility : Evaluating DMARDs and biologics. ( Disease-modifying antirheumatic drugs )

10. Lipopolysaccharide (LPS)-Induced Inflammation Purpose : Model for systemic inflammation. Method : LPS injection. Assessment : Release of pro-inflammatory cytokines. Utility : Studying sepsis and systemic inflammatory response syndrome (SIRS) Formalin-Induced Paw Licking in Rats and Mice Purpose : Model for acute and chronic pain. Method : Formalin injection into the paw. Assessment : Reduction in paw licking behavior. Utility : Studying pain associated with inflammation.

11. Zymosan -Induced Peritonitis in Mice Purpose : Model for peritonitis. Method : Zymosan injection into the peritoneal cavity. Assessment : Reduction in immune cell infiltration and cytokine production. Utility : Evaluating anti-inflammatory effects in peritoneal inflammation. Air Pouch Model in Rats Purpose : Model for localized inflammation. Method : Creation of an air pouch and injection of an inflammatory agent. Assessment : Analysis of exudate for cellular and biochemical markers. Utility : Studying localized inflammation and immune cell infiltration.

12. Carrageenan-Induced Paw Edema Model The Carrageenan-Induced Paw Edema model is one of the most widely used methods for assessing acute inflammation in preclinical studies. This model is particularly valuable for screening nonsteroidal anti-inflammatory drugs (NSAIDs) due to its simplicity, reliability, and reproducibility. The mechanism involves the injection of carrageenan, a polysaccharide extracted from red algae, into the paw of a rat, which leads to localized inflammation and edema (swelling)

13. Method and Procedure Selection of Rats : Strains: Wistar or Sprague- Dawley . Weight: 150-200 grams. Housing: Standard laboratory conditions, 12-hour light-dark cycle, free access to food and water. Acclimatization: At least one week to minimize stress-induced variations. Baseline Measurement : Use a plethysmometer to measure baseline paw volume. Plethysmometer : Water-filled chamber and transducer for detecting water displacement.

14. The plethysmometer consists of a water-filled chamber and a transducer that detects changes in water displacement when the rat's paw is submerged. a transducer is a device that converts a physical change (such as water displacement caused by the submerged paw of a rat) into an electrical signal that can be measured and recorded. Here, the transducer detects changes in water volume or pressure when the rat's paw is submerged, and it translates these changes into a corresponding electrical signal. This signal is then used to quantify th e extent of paw swelling, which is indicative of inflammation or edema in the experimental setting.

15. On the day of the experiment, the baseline paw volume of each rat is measured using a plethysmometer , an instrument designed to measure the volume of a limb. This provides the initial data point against which subsequent measurements will be compared.

16. Carrageenan Solution Preparation : 1% carrageenan solution in saline (0.9% sodium chloride). Heating to ensure dissolution, then cooling to room temperature. Injection Procedure : Light anesthesia for the rats. 0.1 ml carrageenan solution injected subcutaneously into the plantar surface of the right hind paw. Left paw serves as a control. Injection using a 27-gauge needle. Measurement of Paw Edema : Measure paw volume at time 0 (before injection) and at 1, 2, 3, 4, and 6 hours post-injection. Calculate the increase in paw volume (indicative of inflammation) by subtracting baseline volume from post-injection volume.

17. Evaluation of Anti-Inflammatory Activity : Test compounds administered to separate groups of rats prior to carrageenan injection. Control group receives a vehicle (e.g., saline). Measure the ability of the test compound to reduce paw edema. Calculate percentage inhibition of edema: Percentage Inhibition=(Edema volume in control group−Edema volume in test group/Edema volume in control group)×100

18. Significance and Applications Mimics Acute Inflammation : Initial phase characterized by plasma extravasation and cellular infiltration. Release of mediators like histamine, serotonin, bradykinin , and prostaglandins. Relevance to NSAIDs : NSAIDs inhibit prostaglandin synthesis by blocking COX enzymes. Reduces inflammation and swelling. Research and Drug Development : Screens new anti-inflammatory agents before clinical trials. Provides insights into the efficacy and potential side effects of new compounds. Procedure's simplicity and reproducibility make it a staple in pharmacological research.

19. Cotton Pellet Granuloma in Rats The cotton pellet granuloma model is a well-established method for evaluating the chronic inflammatory response in rats. This model involves the surgical implantation of small cotton pellets subcutaneously, leading to the formation of a granuloma , a mass of inflamed tissue. The effectiveness of anti-inflammatory drugs, particularly corticosteroids and other chronic inflammation treatments, is assessed by their ability to reduce the weight of the granuloma formed around the implanted cotton pellets.

20. Method and Procedure Animal Selection and Preparation : Healthy male Wistar or Sprague- Dawley rats, weighing 150-200 grams. Housed under standard laboratory conditions with a 12-hour light-dark cycle and free access to food and water. Acclimatized to the laboratory environment for at least one week to minimize stress-induced variations. Cotton Pellet Preparation : Cotton pellets, approximately 20 ± 1 mg, sterilized in an autoclave to ensure they are free from microbial contamination. Surgical Implantation : Under aseptic conditions, rats are anesthetized using ketamine- xylazine or isoflurane . A small incision is made in the dorsal region, and a subcutaneous pocket is created using blunt dissection. One or two sterile cotton pellets are implanted into the pocket, and the incision is closed with surgical sutures or wound clips. Procedure may be repeated on the opposite side if two pellets are implanted. Post-Surgical Care : Monitoring for signs of distress, infection, or adverse reactions. Administration of analgesics and antibiotics as required. Rats are observed daily after being returned to their cages.

21. Drug Administration : Test compounds are administered to separate groups of rats via oral, intraperitoneal , or other relevant routes. A control group receives a vehicle (e.g., saline) instead of the test compound. Drug treatment starts on the day of pellet implantation and continues daily for 7-14 days. Removal and Analysis of Granuloma : At the end of the treatment period, rats are euthanized. Cotton pellets along with surrounding granuloma tissue are excised. Granuloma tissues are separated, dried at 60°C for 24 hours, and weighed. The dried weight of the granuloma tissue represents the extent of chronic inflammation. Evaluation of Anti-Inflammatory Activity : Effectiveness of the test compound is determined by comparing granuloma weight in treated groups to control group. Percentage inhibition of granuloma formation is calculated using: Percentage Inhibition=(Granuloma weight in control group−Granuloma weight in test group / Granuloma weight in control group)×100

22. Significance and Applications Mimics Chronic Inflammatory Response : Represents prolonged tissue damage and repair processes, leading to granuloma formation. Granulomas consist of macrophages, fibroblasts, and collagen fibers. Evaluation of Anti-Inflammatory Effects : Useful for corticosteroids, which reduce chronic inflammation by inhibiting phospholipase A2 activity. Indicates efficacy of drugs by reduction in granuloma weight. Broader Applications : Used to study other chronic inflammation treatments like NSAIDs, immunosuppressants , and novel anti-inflammatory compounds. Provides insights into therapeutic benefits and safety profiles of drugs before clinical trials.

23. TPA-Induced Ear Edema in Mice The TPA-Induced Ear Edema model is a widely used method for assessing acute inflammation and evaluating the efficacy of topical anti-inflammatory agents. This model involves the topical application of 12-O-tetradecanoylphorbol-13-acetate (TPA ) to the ear of a mouse, which induces acute inflammation characterized by edema (swelling) and erythema (redness). The extent of ear swelling is measured to determine the anti-inflammatory activity of a test compound.

24. Method and Procedure Animal Selection and Preparation : Healthy male or female mice, typically BALB/c or C57BL/6 strains, weighing 20-25 grams. Housed under standard laboratory conditions with a 12-hour light-dark cycle and free access to food and water. Acclimatized to the laboratory environment for at least one week to minimize stress-induced variations. Preparation of TPA Solution : Dissolve 12-O-tetradecanoylphorbol-13-acetate in acetone or ethanol to achieve a concentration of 0.125 mg/ml. Freshly prepare the solution before each experiment to ensure stability and efficacy.

25. Application of TPA : Briefly restrain the mice. Apply 2.5 µl of the TPA solution to the inner and outer surfaces of the right ear using a micropipette. The left ear serves as the control. Ensure even distribution of the solution over the ear surface.

26. Measurement of Ear Edema : Measure ear thickness using a digital caliper or micrometer gauge at baseline (before TPA application) and at 2, 4, and 6 hours post-application. The increase in ear thickness indicates the extent of inflammation and edema. Drug Administration : Administer test compounds topically to the right ear either before or after TPA application, depending on the study design. A control group receives a vehicle (e.g., acetone or ethanol) instead of the test compound. Apply compounds at various concentrations to determine the dose-response relationship.

27. Evaluation of Anti-Inflammatory Activity : Determine the anti-inflammatory activity by comparing ear thickness in treated groups to the control group. Calculate the percentage inhibition of ear edema using the formula: Percentage Inhibition=(Ear thickness in control group−Ear thickness in test group / Ear thickness in control group)×100

28. Significance and Applications Mimics Acute Skin Inflammation : TPA induces inflammation by activating protein kinase C (PKC). Leads to production of pro-inflammatory cytokines like interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-α), and prostaglandins. Results in increased vascular permeability, causing edema and erythema. Advantages : Direct application of test compounds to the inflammation site provides clear and measurable responses. Widely used to evaluate the efficacy of topical corticosteroids, NSAIDs, and novel anti-inflammatory agents. Simple procedure with rapid and reproducible results. Research Applications : Investigate mechanisms of action of anti-inflammatory drugs. Analyze inflammatory mediator levels and histological changes in ear tissue to understand compound modulation of the inflammatory response.

29. Collagen-Induced Arthritis (CIA) in Mice and Rats The Collagen-Induced Arthritis (CIA) model is a widely used experimental model for studying rheumatoid arthritis (RA) in both mice and rats. This model closely mimics many of the clinical and pathological features of human RA , making it invaluable for evaluating the efficacy of disease-modifying anti-rheumatic drugs (DMARDs) and biologics. The induction of arthritis is achieved through immunization with type II collagen, leading to an autoimmune response that results in joint inflammation and destruction.

30. Method and Procedure Animal Selection and Preparation : Healthy male or female mice (DBA/1 or C57BL/6 strains) or rats (Lewis or Sprague- Dawley strains). Housed under standard laboratory conditions with a 12-hour light-dark cycle and free access to food and water. Acclimatized to the laboratory environment for at least one week to minimize stress-induced variations. Preparation of Collagen Emulsion : Type II collagen (from chicken sternum) dissolved in 0.1 M acetic acid to a concentration of 2 mg/ml. Emulsified with an equal volume of complete Freund's adjuvant (CFA) to form a thick emulsion . Emulsification involves repeated passage through a syringe until a stable emulsion is achieved. Induction of Arthritis : Animals are lightly anesthetized to reduce stress during injection. For mice: 100 µl of the collagen emulsion injected intradermally at the base of the tail. For rats: 200 µl of the emulsion injected at multiple sites along the base of the tail. A booster injection of collagen in incomplete Freund's adjuvant (IFA) is administered 21 days later to enhance the immune response and ensure robust arthritis development.

31. Development and Assessment of Arthritis : Arthritis typically develops within 2-3 weeks post-immunization. Regular examination of hind paws and forepaws for signs of erythema (redness), swelling, and deformity. Severity of arthritis scored using a standard clinical scoring system : : No swelling or redness 1 : Mild swelling and/or redness in one joint 2 : Moderate swelling and/or redness in more than one joint 3 : Severe swelling and/or redness in the entire paw 4 : Deformity and/or ankylosis (joint fusion) Total arthritis score for each animal calculated by summing the scores of all four paws. Histopathological Analysis : At the end of the study, animals are euthanized, and joints are harvested for histopathological examination. Tissues are fixed in 10% formalin, decalcified, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E). Assess histological features such as synovial hyperplasia, inflammatory cell infiltration, pannus formation, and cartilage and bone erosion to confirm joint damage.

32. Drug Administration : Test compounds administered to separate groups of animals starting from the day of arthritis induction or at the onset of clinical symptoms. Administration routes can be oral, intraperitoneal , or subcutaneous, depending on the pharmacokinetics of the test compound. A control group receives a vehicle instead of the test compound. Evaluation of Anti-Arthritic Activity : Efficacy of the test compound evaluated by comparing clinical scores, paw swelling measurements, and histopathological findings in treated groups to control group. Reduction in clinical scores, decreased paw swelling, and improved histological appearance indicate anti-arthritic activity.

33. Significance and Applications Mimics Human Rheumatoid Arthritis (RA) : Generates an immune response against type II collagen. Produces autoantibodies, activates T cells, and releases pro-inflammatory cytokines like TNF-α, IL-1β, and IL-6. These mediators drive inflammation and joint destruction, closely resembling human RA progression. Evaluation of DMARDs and Biologics : Useful for evaluating drugs like methotrexate and agents targeting TNF-α. Provides insights into mechanisms of anti-rheumatic drugs by analyzing immune cell profiles, cytokine levels, and histopathological changes. Helps understand how compounds modulate the immune response and protect joints. Research and Drug Development : Provides valuable data on the potential therapeutic benefits and safety profiles of new compounds. Aids in preclinical screening before advancing to clinical trials.

34. Lipopolysaccharide (LPS)-Induced Inflammation The Lipopolysaccharide (LPS)-Induced Inflammation model is a widely used experimental method to study systemic inflammation and sepsis in preclinical research . LPS, a major component of the outer membrane of Gram-negative bacteria, acts as a potent endotoxin that triggers a robust inflammatory response when introduced into an organism. This model is particularly useful for evaluating the efficacy of anti-inflammatory drugs and understanding the mechanisms underlying inflammation and immune response.

35. Method and Procedure Animal Selection and Preparation : Healthy male or female rodents, typically BALB/c or C57BL/6 mice, or Wistar or Sprague- Dawley rats. Housed under standard laboratory conditions with a 12-hour light-dark cycle and free access to food and water. Acclimatized to the laboratory environment for at least one week to minimize stress-induced variations. Preparation of LPS Solution : LPS typically obtained from Escherichia coli (E. coli) and dissolved in sterile saline or phosphate-buffered saline (PBS). Desired concentration varies depending on species and severity of the inflammatory response (common concentrations range from 0.1 to 10 mg/kg). Administration of LPS : Administered via intraperitoneal ( i.p .), intravenous ( i.v. ), or subcutaneous ( s.c. ) injection, depending on the study's objectives. Intraperitoneal or intravenous injections are commonly used for systemic inflammation.

36. Monitoring and Assessment of Inflammation : Close monitoring for signs of systemic inflammation typically manifesting within a few hours. Clinical signs include lethargy, piloerection (hair standing on end), hypothermia, reduced food and water intake, and weight loss. Severity of symptoms can be scored using a clinical scoring system. Measurement of Inflammatory Markers : Blood samples collected at various time points post-LPS administration to measure levels of inflammatory markers such as TNF-α, IL-1β, IL-6, and CRP. Quantified using enzyme-linked immunosorbent assay (ELISA) or multiplex cytokine assays. Histopathological Analysis : Animals euthanized at the end of the study, and tissues such as liver, spleen, lungs, and kidneys harvested for examination. Tissues fixed in 10% formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E). Histological analysis focuses on leukocyte infiltration, tissue necrosis, and edema.

37. Drug Administration : Test compounds administered to separate groups of animals prior to or after LPS injection, depending on study design. Administration routes can be oral, intraperitoneal , or intravenous, tailored to the pharmacokinetics of the test compound. A control group receives a vehicle instead of the test compound. Evaluation of Anti-Inflammatory Activity : Anti-inflammatory activity evaluated by comparing clinical signs, cytokine levels, and histopathological findings in treated groups to control group. Reduction in clinical symptoms, lower cytokine levels, and improved histological appearance indicate anti-inflammatory efficacy.

38. Significance and Applications Mimics Systemic Inflammation and Sepsis : LPS acts as a potent endotoxin, triggering robust inflammatory responses. Useful for studying the mechanisms underlying inflammation and immune response. Evaluation of Anti-Inflammatory Drugs : Provides a platform for testing the efficacy of potential anti-inflammatory drugs. Helps in understanding the pharmacodynamics and pharmacokinetics of new compounds.

39. Significance and Applications The LPS-Induced Inflammation model is crucial for mimicking systemic inflammatory response syndrome (SIRS) and sepsis, conditions marked by severe inflammation and multi-organ dysfunction. LPS injection activates Toll-like receptor 4 (TLR4) on immune cells, triggering pro-inflammatory cytokine production and various inflammatory pathways.

40. Key Applications : Mimicking SIRS and Sepsis : Models severe inflammation and multi-organ dysfunction. Simulates clinical conditions seen in SIRS and sepsis. Evaluation of Anti-Inflammatory Agents : Tests the efficacy of drugs targeting cytokines, signaling molecules, and immune cell activation. Useful for screening potential therapeutic compounds. Studying Sepsis Pathophysiology : Provides insights into the mechanisms of sepsis. Helps identify therapeutic targets for intervention. Understanding Inflammation Mechanisms : Analyzes cytokine levels, signaling pathway activation, and tissue changes. Enhances understanding of how inflammation is regulated. Drug Screening and Development : Provides insights into the pharmacodynamics and pharmacokinetics of new compounds. Assesses therapeutic benefits and safety profiles of new drugs before clinical trials. Immune Response Regulation : Studies the regulation of immune responses during inflammation. Helps develop strategies to modulate inflammatory responses therapeutically.

41. Formalin-Induced Paw Licking in Rats and Mice The Formalin-Induced Paw Licking model is a widely used method for assessing pain and inflammation in preclinical research. This model involves the injection of formalin into the paw of rats or mice, inducing a biphasic pain response. The formalin test is particularly valuable for evaluating the efficacy of analgesic and anti-inflammatory drugs.

42. Method and Procedure Animal Selection and Preparation : Healthy male or female rats ( Wistar or Sprague- Dawley ) or mice (BALB/c or C57BL/6). Housed under standard laboratory conditions with a 12-hour light-dark cycle and free access to food and water. Acclimatized to the laboratory environment for at least one week to minimize stress-induced variations. Preparation of Formalin Solution : Commonly used concentrations : 2.5% or 5% formalin (formaldehyde in saline). The concentration can be adjusted based on the desired pain response intensity. Freshly prepared before each experiment to ensure consistency. Injection Procedure : Animal gently restrained. 20 µl of formalin solution injected subcutaneously into the plantar surface of the right hind paw using a fine needle (27-gauge for mice, 30-gauge for rats). Care taken to ensure accurate delivery into the paw tissue.

43. Observation and Measurement of Paw Licking Behavior : Phase 1 (Acute Pain Phase) : Occurs within the first 5 minutes post-injection. Due to the direct activation of nociceptors by formalin. Phase 2 (Inflammatory Pain Phase) : Occurs between 15 to 60 minutes post-injection. Due to the inflammatory response and sensitization of nociceptors . Animal behavior observed continuously for 60 minutes post-injection. Total time spent licking, biting, or shaking the injected paw recorded in both phases . Duration of pain behaviors indicates pain intensity. Drug Administration : Test compounds administered to separate groups prior to formalin injection. Administration route: oral, intraperitoneal , or any other relevant route depending on pharmacokinetics. Control group receives a vehicle (e.g., saline) instead of the test compound.

44. Evaluation of Analgesic and Anti-Inflammatory Activity : Efficacy determined by comparing time spent in paw licking behavior in treated groups to control group. Percentage inhibition of pain behaviors calculated for both phases using: Percentage Inhibition=(Time spent licking in control group−Time spent licking in test group / Time spent licking in control group)×100

45. Significance and Applications Biphasic Pain Response : Phase 1 : Useful for studying drugs targeting acute nociceptive pain (e.g., local anesthetics). Phase 2 : Valuable for assessing drugs that modulate inflammatory pain and central sensitization (e.g., NSAIDs, opioids). Screening Analgesic and Anti-Inflammatory Agents : Provides valuable insights into drug efficacy in reducing both immediate and prolonged pain responses. Simple procedure with clear, quantifiable endpoints makes it reliable and reproducible. Understanding Pain and Inflammation Mechanisms : Analyzing behavioral responses and correlating with biochemical markers of inflammation. Gaining deeper insights into how different drugs modulate pain pathways and inflammatory processes.

46. Air Pouch Model in Rats The Air Pouch Model in rats is a valuable experimental method used to study localized inflammation and evaluate the efficacy of anti-inflammatory drugs. This model involves the creation of a subcutaneous air-filled pouch that can be used to induce and analyze inflammatory responses . It is particularly useful for examining the recruitment of immune cells, the production of inflammatory mediators, and the effects of pharmacological agents on these processes.

47. Recruitment of Immune Cells in the Context of the Air Pouch Model Recruitment of immune cells refers to the process by which immune cells are attracted and moved to a site of inflammation or infection. In the context of the Air Pouch Model , this process involves the following steps:

48. Induction of Inflammation : An irritant or inflammatory agent is injected into the air pouch created under the skin of an animal, typically a rodent. This leads to the production of signaling molecules known as chemokines and cytokines . Release of Signaling Molecules : The local cells in the tissue where the air pouch is created release chemokines and cytokines in response to the inflammatory agent. These molecules serve as chemical signals that attract immune cells. Migration of Immune Cells : Immune cells from the bloodstream detect these signals and migrate towards the site of inflammation. The primary types of immune cells involved include neutrophils , macrophages , and lymphocytes .

49. Accumulation at the Inflammation Site : These immune cells accumulate in the air pouch, where they participate in the inflammatory response. They help to eliminate the irritant, clear damaged tissue, and contribute to the overall inflammatory process. Analysis of Immune Response : Researchers can then collect the exudate (fluid) from the air pouch to analyze the types and quantities of immune cells present, as well as the levels of inflammatory mediators. This helps in understanding how different substances, such as potential anti-inflammatory drugs, affect the recruitment and function of immune cells. By studying the recruitment of immune cells in the Air Pouch Model, researchers can gain insights into the mechanisms of inflammation and evaluate the effectiveness of new anti-inflammatory treatments.

50. Method and Procedure Animal Selection and Preparation : Healthy male Wistar or Sprague- Dawley rats, weighing 200-250 grams. Housed under standard laboratory conditions with a 12-hour light-dark cycle and free access to food and water. Acclimatized to the laboratory environment for at least one week to minimize stress-induced variations. Creation of the Air Pouch : Initial Air Injection (Day 0) : Rats are lightly anesthetized using an appropriate anesthetic (e.g., isoflurane ). A sterile 21-gauge needle is used to inject 20 ml of sterile air subcutaneously into the dorsal area to create an air pouch . Reinforcement of the Pouch (Day 3) : An additional 10 ml of sterile air is injected into the same site to maintain the air pouch and allow for its stabilization and vascularization.

51. Induction of Inflammation : Day 6 : Inflammation is induced by injecting an inflammatory agent, such as carrageenan (1% in saline) or lipopolysaccharide (LPS) (1 mg/ml in saline), into the air pouch. Typically, 2 ml of the inflammatory agent is injected, inducing a localized inflammatory response characterized by the recruitment of immune cells and the production of inflammatory mediators. Sample Collection : After a specified period, usually 4 to 24 hours post-injection, the rats are euthanized. The exudate (fluid) from the air pouch is collected using a sterile syringe. The exudate volume is measured, and the samples are centrifuged to separate the cellular components from the supernatant. The cell pellet is resuspended in phosphate-buffered saline (PBS) for further analysis.

52. Analysis of Inflammatory Response : Leukocyte Count : The total number of leukocytes (white blood cells) in the exudate is determined using a hemocytometer or an automated cell counter. Differential cell counts (e.g., neutrophils, macrophages, lymphocytes) are performed using stained cytospin preparations. Cytokine Levels : The levels of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF- α), interleukin-1 beta (IL-1 β), and interleukin-6 (IL-6), in the exudate supernatant are measured using enzyme-linked immunosorbent assay (ELISA) or multiplex cytokine assays. Protein Concentration : The protein concentration in the exudate is determined using a protein assay (e.g., Bradford assay) to assess the extent of plasma extravasation and vascular permeability. Histological Examination : The air pouch tissue can be harvested, fixed in formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E) for histopathological analysis of inflammatory cell infiltration and tissue changes.

53. Drug Administration : Test compounds (potential anti-inflammatory drugs) are administered to separate groups of rats either before or after the induction of inflammation. Administration routes can be oral, intraperitoneal , or subcutaneous, depending on the pharmacokinetics of the test compound. A control group receives a vehicle (e.g., saline) instead of the test compound. Evaluation of Anti-Inflammatory Activity : The efficacy of the test compound is evaluated by comparing the exudate volume, leukocyte counts, cytokine levels, and histopathological findings in the treated groups to those in the control group. Reduction in exudate volume , lower leukocyte counts, decreased cytokine levels, and improved histological appearance indicate the anti-inflammatory activity of the test compound.

54. Significance and Applications The Air Pouch Model is significant for its ability to mimic localized inflammation and for its application in screening anti-inflammatory drugs. The air pouch provides a controlled environment for inducing inflammation and allows for the easy collection of exudate for analysis. This model is particularly useful for studying the recruitment of immune cells, the production of inflammatory mediators, and the effects of pharmacological agents on these processes.

55. In Vitro Screening Methods for Antiinflammatory Drugs 1. Enzyme Inhibition Assays These assays measure the ability of a compound to inhibit enzymes that play a key role in inflammation. Common targets include: Cyclooxygenase (COX) Inhibition : This involves measuring the inhibition of COX-1 and COX-2 enzymes, which are responsible for the production of prostaglandins, mediators of inflammation. 5-Lipoxygenase (5-LOX) Inhibition : This enzyme is involved in the production of leukotrienes , another group of inflammatory mediators.

56. 2. Cytokine Assays Cytokines such as TNF-α, IL-1β, IL-6, and IL-8 are significant mediators of inflammation. In these assays, the effect of a compound on the production or secretion of these cytokines is measured. ELISA (Enzyme-Linked Immunosorbent Assay) : Used to quantify specific cytokines in cell culture supernatants. Multiplex Assays : Allow simultaneous measurement of multiple cytokines.

57. 3. Cell Viability and Proliferation Assays These assays determine whether a compound has cytotoxic effects or modulates the proliferation of immune cells, such as macrophages or lymphocytes. MTT or MTS Assays : Measure cell metabolic activity as an indicator of viability and proliferation. Trypan Blue Exclusion Test : Used to determine the number of viable cells present in a sample.

58. Enzyme Inhibition Assay Procedures 1. Cyclooxygenase (COX) Inhibition Assay Objective : To measure the ability of a compound to inhibit the activity of COX-1 and COX-2 enzymes.

59. Procedure : Preparation of Enzyme Solution : Dilute the COX-1 and COX-2 enzymes to the desired concentration in a suitable buffer (e.g., Tris buffer, pH 7.4). Substrate Preparation : Prepare a stock solution of arachidonic acid. It may be necessary to dissolve the arachidonic acid in ethanol or DMSO before diluting it with buffer. Reaction Setup : Add the enzyme solution to a microplate well. Add the test compound (potential inhibitor) to the well and incubate for a specific period (e.g., 15-30 minutes) to allow for binding. Add the arachidonic acid substrate to initiate the reaction.

60. Coupled Reaction (for Colorimetric Assay) : Add hemoglobin or peroxidase and a colorimetric reagent (e.g., TMPD - N,N,N′,N′- tetramethyl -p- phenylenediamine ) to the reaction mixture. The peroxidase converts the prostaglandin product to a colored compound. Incubation : Incubate the reaction mixture at 37°C for a specific period (e.g., 5-10 minutes) to allow the reaction to proceed. Measurement : For a colorimetric assay, measure the absorbance at the appropriate wavelength (e.g., 590 nm) using a microplate reader. For a fluorometric assay, measure the fluorescence intensity using a fluorometer . Data Analysis : Calculate the enzyme activity in the presence and absence of the test compound. Determine the percentage inhibition by comparing the enzyme activity with and without the inhibitor. Control Experiments : Include controls with no inhibitor (positive control) and with a known inhibitor (negative control) to validate the assay.

61. 2. 5-Lipoxygenase (5-LOX) Inhibition Assay Objective : To measure the ability of a compound to inhibit the activity of the 5-LOX enzyme. Procedure : Preparation of Enzyme Solution : Dilute the 5-LOX enzyme to the desired concentration in a suitable buffer. Substrate Preparation : Prepare a stock solution of arachidonic acid. It may need to be dissolved in ethanol or DMSO before dilution with buffer. Reaction Setup : Add the enzyme solution to a microplate well. Add the test compound (potential inhibitor) to the well and incubate for a specific period (e.g., 15-30 minutes) to allow for binding. Add the arachidonic acid substrate to initiate the reaction.

62. Incubation : Incubate the reaction mixture at 37°C for a specific period (e.g., 5-10 minutes) to allow the reaction to proceed. Detection (for Spectrophotometric Assay) : Measure the absorbance change associated with the formation of hydroperoxides using a microplate reader at an appropriate wavelength (e.g., 234 nm). Detection (for Chemiluminescent Assay) : Add a chemiluminescent reagent to the reaction mixture and measure the light emission using a chemiluminescence detector.

63. Measurement : For a spectrophotometric assay, measure the absorbance at the appropriate wavelength. For a chemiluminescent assay, measure the light emission intensity. Data Analysis : Calculate the enzyme activity in the presence and absence of the test compound. Determine the percentage inhibition by comparing the enzyme activity with and without the inhibitor. Control Experiments : Include controls with no inhibitor (positive control) and with a known inhibitor (negative control) to validate the assay.